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Purpose: The purpose of this study was to define the prevalence of undiagnosed airflow obstruction 
(AO) among subjects with a history of smoking but no previous diagnosis of chronic lung disease. 
The finding of AO likely represents diagnosis of chronic obstructive pulmonary disease. 
Patients: People aged $30 years with a history of smoking who attended public outpatient 
clinics for primary care services were included in this study.
Methods: A cross-sectional survey in five clinics in Hong Kong using the Breathlessness, Cough, 
and Sputum Scale, the Lung Function Questionnaire, and office spirometry was conducted.
Results: In total, 731 subjects (response rate =97.9%) completed the questionnaires and spiro-
metry tests. Most of the subjects were men (92.5%) in the older age group (mean age =62.2 years; 
standard deviation =11.7). Of the 731 subjects, 107 had AO, giving a prevalence of 14.6% (95% 
confidence interval =12.1–17.2); 45 subjects with AO underwent a postbronchodilator test. 
By classifying the severity of chronic obstructive pulmonary disease using the Global Initiative 
for Chronic Obstructive Lung Disease, 27 (60%) were considered to be in mild category and 
18 (40%) in moderate category. None of them belonged to the severe or very severe category. 
The total score of Lung Function Questionnaire showed that majority of the subjects with 
AO also had chronic cough, wheezing attack, or breathlessness, although most did not show 
any acute respiratory symptoms in accordance with the Breathlessness, Cough, and Sputum 
Scale. Diagnosis of AO was positively associated with the number of years of smoking (odds 
ratio =1.044, P=0.035) and being normal or underweight (odds ratio =1.605, P=0.046). It was 
negatively associated with a history of hypertension (odds ratio =0.491, P=0.003).
Conclusion: One-seventh of smokers have undiagnosed AO. Spirometry screening of smokers 
should be considered in order to diagnose AO at an early stage, with an emphasis on smoking 
cessation.
Keywords: chronic obstructive pulmonary disease, COPD, airflow obstruction, smokers, early 
diagnosis, general practice
Introduction
Chronic obstructive pulmonary disease (COPD) causes suffering and adds substantial 
burden to national health care budget because of repeated hospital admissions.1 How-
ever, the condition often remains undiagnosed until the patients are sent to the emergency 
room with acute exacerbation or complications such as pneumonia or pneumothorax, 
by which time the disease is often already in the advanced stage.2 In 2002, COPD 
was the fifth leading cause of mortality worldwide. Total deaths from COPD are pro-
jected to increase by .30% in the next 10 years.3 The estimated overall prevalence of 
COPD among the general population varies among different regions, with 6.3% in the 
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Asia-Pacific region,4 8.2% in the People’s Republic of China,5 
4% in the UK, and 6% in the USA.6 In Hong Kong, the COPD 
prevalence was 3.5% among those aged .30 years estimated 
using epidemiology relationship of smoking and other risk 
factors.4 In the community, 25.9% of those aged .60 years 
attending elderly centers were found to have airflow obstruc-
tion (AO) in a survey using office spirometry.7
Early COPD diagnosis may motivate smoking cessation, 
which is the only measure known to radically improve future 
prospects for the patients.8–10 One feasible method for early 
COPD diagnosis is to screen for AO. AO is spirometrically 
defined as a reduced ratio of forced expiratory volume in the 
first second (FEV
1
) to forced vital capacity (FVC), such that 
FEV
1
/FVC is ,0.70. The yield of undiagnosed AO patients 
is highly dependent on the inclusion criteria of the high-risk 
group. For instance, history of smoking is known to be a 
strong risk factor for AO.11
Although the most common diagnosis in smokers with 
AO is COPD,12 doctors still need to consider other differential 
diagnoses such as asthma, bronchiectasis,13 and pulmonary 
tuberculosis.14 Patients with AO are often relatively asymp-
tomatic in the early stages. Smokers, men, and older people 
have a higher risk of being affected.15 The prevalence of 
undiagnosed AO among people with smoking history varies 
worldwide,12 and it ranges from 10.1% in the UK,16 13.1% in 
Japan,17 and 34.8% in Denmark among smokers with chronic 
respiratory symptoms.18 
It is generally agreed that primary health care profession-
als play a significant role in accurately diagnosing COPD at 
the early stage.19 They have ample opportunities to make a 
diagnosis during primary health care encounters.20 The active 
case finding of high-risk group can potentially identify 70% 
more undiagnosed AO than opportunistic identification alone. 
Providing treatment for these new cases could potentially 
reduce hospitalizations and deaths.21 The most commonly 
used strategy is to invite patients in the high-risk group to 
complete questionnaires and perform spirometry during 
their primary care visits,16–18,20 although it is questionable 
whether such strategy is applicable and acceptable in older 
population from the lower socioeconomic class. In view of 
the large variability of response and yield in COPD screening 
programs worldwide, this study was conducted to examine 
the situation in Hong Kong.
Hypothesis to be tested
This study investigates the prevalence of AO among 
persons aged $30 years who have a history of smoking 
but had no previous diagnosis of obstructive lung 
diseases. In addition, it investigates whether there is any 
significant association of AO with demographic and clini-
cal parameters. 
Materials and methods
This is a multicenter cross-sectional prevalence study per-
formed from April to July 2014. The study was approved by 
the Hong Kong Hospital Authority, Kowloon West Cluster 
Research Ethics Committee. Written informed consent 
was obtained before the commencement of spirometry and 
data collection. Subjects with acute respiratory symptoms 
underwent a spirometry test 2–6 weeks later to ensure the 
reliability of the result.
setting
This study was conducted in five public primary care commu-
nity clinics in the Kwai Chung and Tsing Yi districts of Hong 
Kong. The study clinics mainly provide primary health care 
services to the older population from lower socioeconomic 
class, and ~10% of the patients attending the study clinics 
were active smokers. A number comparable to the prevalence 
of daily smokers in the Hong Kong adult population.22 All 
Hong Kong residents have access to the clinics’ smoking ces-
sation counseling service with or without referral. Doctors can 
arrange for any patient to do an office spirometry. In the Hong 
Kong primary care setting, only a small proportion of physi-
cian-diagnosed COPD patients have documented spirometry 
findings.23 In the absence of any structured COPD screening 
program, and with the uncommon use of spirometry for the 
evaluation of patients with chronic respiratory symptoms, the 
prevalence of undiagnosed AO is anticipated to be high, espe-
cially among high-risk patients such as chronic smokers.
Study subjects
All potential subjects were identified by using computerized 
patient records with a history of smoking, regardless of their 
reason for consultation. They were then recruited by trained 
research nurses during their next visit to the clinics for health 
care services. 
Inclusion and exclusion criteria
All subjects must be aged $30 years with a history of 
smoking (ie, persons who reported smoking at least 
100 cigarettes during their lifetime, according to the 2011 
Centre of Disease Control and Prevention Criteria).24 Sub-
jects who were unable to perform spirometry and who had 
previous diagnosis of chronic lung diseases including asthma, 
COPD, pulmonary fibrosis, bronchiectasis, and restrictive 
lung disease were excluded from this study. Pregnant women 
were also excluded from the study.
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Basic data collection
The research nurses interviewed participants using standard 
questionnaires in Cantonese (a variety of the Chinese lan-
guages) to collect the following data:
•	 Demographics: sex, age, and occupation.
•	 Smoking status, including intensity and duration by using 
the World Health Organization Global Adult Tobacco 
Survey.24
•	 Known chronic illnesses according to subjects’ medical 
record.
•	 Assessment of acute respiratory symptoms by using the 
validated Chinese version of Breathlessness, Cough, and 
Sputum Scale (BCSS)© 2003,25 used with permission from 
the AstraZeneca Company (London, UK).
•	 Assessment of chronic respiratory symptoms by using 
the Chinese version of Lung Function Questionnaire 
(LFQ),26 used with permission from GlaxoSmithKline 
plc (Middlesex, UK).
The BCSS is a three-item, patient-reported questionnaire 
regarding the presence of three common COPD symptoms 
during the interview: breathlessness, cough, and sputum. 
Subjects were asked to evaluate each symptom on a 5-point 
Likert-type scale, ranging from 0 to 4, with higher scores 
indicating more severe manifestation of symptoms. The 
total score is expressed in the range of 0–12. The tool has 
been validated to assess daily respiratory symptoms in 
COPD patients.27
The LFQ is a five-item tool asking how often the subject 
experiences productive cough, wheezing attack, and short-
ness of breath by a 5-point Likert-type scale. The fourth item 
is the number of years of smoking, and the fifth item is the age 
of the subject. The total score ranges from 5 (very frequent 
symptoms) to 25 (never had any symptoms). A score of #18 
indicates the presence of chronic respiratory symptoms and 
high risk of AO. The tool has been used to estimate the preva-
lence of COPD among smokers in primary care settings. It 
provides additional information to identify high-risk patients 
with AO.28 The Chinese version of LFQ was translated by 
bilingual authors Margaret Choi-Hing Lam and Sau Nga Fu 
and subsequently back-translated by Wai Cho Yu; all authors 
agreed on the final version. The translated LFQ was tested 
on five subjects to confirm content validity.
spirometry
Spirometry was done according to the American Thoracic 
Society criteria29 by trained research nurses using the 
Spirolab III® spirometer (MIR Medical International 
Research, Roma, Italy) with subjects in seated position. 
The spirometric  reference values for Hong Kong adults 
according to Ip et al were adopted.30 For those with FEV
1
/
FVC ,0.70, spirometry was repeated 15–20 minutes 
after inhalation of 400 µg Ventolin® metered dose inhaler 
(salbutamol; GlaxoSmithKline plc) administered using a 
spacer. Each spirogram was reviewed using the American 
Thoracic Society guidelines.29 Positive bronchodilator (BD) 
reversibility is defined as an increase in FEV
1
 of 200 mL 
and 12%.29 
Outcome measurement
The primary outcome is the proportion of subjects with AO, 
defined by preBD FEV
1
/FVC ratio of ,0.70.
Secondary outcomes are:
•	 proportion of subjects with AO and chronic respiratory 
symptoms, assumed by LFQ score #18, indicating a high 
possibility of COPD; 
•	 proportion of subjects with different Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) stages 
according to the postBD FEV
1
 % predicted value of Hong 
Kong adults;30 and 
•	 factors associated with AO.
statistical analysis
Descriptive statistics were presented as mean and standard 
deviation (SD) for continuous variables and as a proportion 
for categorical variables. The prevalence rate of undiagnosed 
AO and its 95% confidence interval were calculated. Socio-
demographic and clinical characteristics between subjects 
with and without undiagnosed AO were compared and tested 
using a χ2 test for categorical variables and independent t-test 
and Fisher’s exact test for continuous variables. Among 
those who underwent postBD spirometry, the proportions 
of subjects with mild, moderate, severe, and very severe 
conditions according to the GOLD stage standard were 
reported.
Since undiagnosed AO is the primary outcome, logistic 
regression model was used to determine sociodemographic 
and clinical factors associated with the presence of undi-
agnosed AO. Odds ratios (ORs) of sociodemographic and 
clinical factors associated with undiagnosed AO were esti-
mated. All significance tests were two-tailed, and P,0.05 
was considered significant. Statistical analyses were 
conducted by using SPSS Version 23.0 (IBM® SPSS Inc., 
Armonk, NY, USA).
Results
Subject characteristics
Figure 1 presents the research workflow. Of the 770 eligible 
subjects approached, 16 refused to participate (response 
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rate =97.9%), and 23 subjects were excluded due to the 
following conditions: pregnancy (n=1), having kyphoscoliosis 
(n=2), being physically unfit to blow (n=11), and having 
known chronic lung disease (n=9). The remaining 731 subjects 
completed the questionnaires and spirometry tests. Table 1 
shows the sociodemographic and clinical characteristics of 
the subjects. Most of the subjects were men (92.5%) in the 
older age group (mean age =62.2 years; SD =11.7). The 
majority of them (73.1%) only attended middle school or 
below. One-third (32.4%) of them were actively employed. 
Approximately half of them (48.3%) were current smokers, 
with all being cigarette smokers except for one bamboo 
pipe smoker. The mean years since first smoking was 42.9 
(SD =12.9). The mean pack-year was 34.2 (SD =25.1). Many 
subjects were either overweight (24.1%) or obese (47.1%) 
according to the World Health Organization Asian body mass 
index cutoff level.31 Two-third of them had hypertension, and 
one-third of them had diabetes mellitus. The mean BCSS 
score was 0.95 (SD =1.12). In total, 335 subjects (45.8%) had 
no acute respiratory symptoms (BCSS score =0), while 381 
(52.1%) had only mild acute symptoms (BCSS score =1–3). 
Of the 105 subjects with AO who responded to LFQ, 100 
(95.2%) scored #18 in LFQ, which indicated the presence 
of significant chronic respiratory symptoms.
spirometry results
Table 2 shows the spirometry results of the 731 subjects. 
107 were found to have AO determined by a preBD 
FEV
1
/FVC ratio of ,0.70. The prevalence was 14.6% 
(95% confidence interval =12.1–17.2). In other words, one in 
seven subjects were screened positive for AO. The Pearson’s 
correlation between FEV
1
 % predicted and LFQ was 0.282 
(P=0.004). The higher LFQ score (less chronic symptoms) 
indicated a higher FEV
1
 % predicted in spirometry test.
A significant number of subjects refused to undergo the 
postBD test. Of the 45 subjects (42.1%) who completed 
postBD spirometry, 12 (20.7%) showed significant BD 
reversibility. Assuming that the subjects with AO were 
suffering from COPD, the GOLD classification of severity 
of COPD showed that conditions of 60% of the subjects 
were mild, while that of 40% were moderate. None of the 
subjects were classified as suffering from severe or very 
severe COPD.
Factors associated with airflow 
obstruction
Table 3 shows the sociodemographic and clinical factors asso-
ciated with AO and AO with chronic respiratory symptoms 
(LFQ score #18) by logistic regression. Sex, educational level, 
?????????????????????????????????????????????? ???????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????
?????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????
????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????
Figure 1 Study workflow and outcome measurement.
Abbreviations: AO, airflow obstruction; BCSS, Breathlessness, Cough, and Sputum Scale; BD, bronchodilator; FEV1, forced expiratory volume in the first second; FVC, 
forced vital capacity; LFQ, Lung Function Questionnaire.
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and occupation of the subjects were not significantly associ-
ated with the presence of AO. The longer the subjects have 
smoked, the more likely they would have AO (total number of 
years of smoking, OR =1.04; P=0.035). However, the number 
of pack-years did not demonstrate a significant association. 
Some clinical parameters were also found to show posi-
tive association with AO and AO with chronic respiratory 
symptoms. Subjects with body mass index ,23 kg/m2 (normal 
or underweight) were more likely to have AO (OR =1.61; 
P=0.046). There were 537 (73.5%) subjects with pre-
defined chronic illnesses such as cardiovascular diseases, 
hypertension, diabetes mellitus, and ischemic heart disease 
for at least 6 months. Subjects with hypertension were found 
less likely to have AO (OR =0.49; P=0.003). Having other 
chronic illnesses did not show any significant association 
with AO.
Table 1 Sociodemographic and clinical characteristics of subjects with history of smoking in primary care setting
Characteristics Total (n=731) Airflow obstruction: FEV1/FVC ,0.7
Yes (n=107) No (n=624) P-value*
Sociodemographic
Age (years; mean ± sD) 62.2±11.7 68.2±9.7 61.2±11.8 ,0.001
sex, n (%) 0.226
Male 676 (92.5%) 102 (95.3%) 574 (92.0%)
Female 55 (7.5%) 5 (4.7%) 50 (8.0%)
education, n (%) 0.188
Primary or below 338 (46.2%) 59 (55.1%) 279 (44.7%)
Middle school 197 (26.9%) 29 (27.1%) 168 (26.9%)
high school 153 (20.9%) 14 (13.1%) 139 (22.3%)
University or above 26 (3.6%) 3 (2.8%) 23 (3.7%)
Unknown 17 (2.3%) 2 (1.9%) 15 (2.4%)
Occupation, n (%) 0.017
retired 369 (50.5%) 72 (67.3%) 297 (47.6%)
Unemployed 36 (4.9%) 5 (4.7%) 31 (5.0%)
housewife 18 (2.5%) 1 (0.9%) 17 (2.7%)
Working 237 (32.4%) 24 (22.4%) 213 (34.1%)
Others or unknown 71 (9.7%) 5 (4.7%) 66 (10.6%)
smoking status, n (%) 0.948
Current smoker 353 (48.3%) 52 (48.6%) 301 (48.2%)
Daily smoker 329 (45.0%) 49 (45.8%) 280 (44.9%)
nondaily smoker 24 (3.3%) 3 (2.8%) 21 (3.4%)
Past smoker 378 (51.7%) 55 (51.4%) 323 (51.8%)
Years since first smoking (years; mean ± sD) 42.9±12.9 50.1±11.3 41.6±12.8 ,0.001
Pack-years (mean ± sD) 34.2±25.1 38.7±26.5 33.4±24.8 0.046
Clinical
Body weight (kg; mean ± sD) 66.9±11.4 65.0±12.4 67.3±11.1 0.056
Body height (m; mean ± sD) 1.6±0.1 1.6±0.1 1.6±0.1 0.924
BMI (kg/m2; mean ± sD) 25.0±3.6 24.2±3.3 25.2±3.6 0.011
BMI cutoff, n (%) 0.010
Underweight (,18.5 kg/m2) 14 (1.9%) 2 (1.9%) 12 (1.9%)
normal ($18.50–,23 kg/m2) 197 (26.9%) 43 (40.2%) 154 (24.7%)
Overweight ($23–,25 kg/m2) 176 (24.1%) 20 (18.7%) 156 (25.0%)
Obese ($25 kg/m2) 344 (47.1%) 42 (39.3%) 302 (48.4%)
hypertension, n (%) 453 (62.0%) 59 (55.1%) 394 (63.1%) 0.115
Diabetes, n (%) 242 (33.1%) 29 (27.1%) 213 (34.1%) 0.153
Ischemic heart disease, n (%) 38 (5.2%) 9 (8.4%) 29 (4.6%) 0.105
stroke, n (%) 43 (5.9%) 5 (4.7%) 38 (6.1%) 0.565
Chronic pain for at least 6 months, n (%) 4 (0.5%) 1 (0.9%) 3 (0.5%) 0.470
Other heart disease, n (%) 14 (1.9%) 3 (2.8%) 11 (1.8%) 0.444
Other lung disease, n (%) 2 (0.3%) 0 (0.0%) 2 (0.3%) 1.000
Chronic illness, n (%) 537 (73.5%) 74 (69.2%) 463 (74.2%) 0.275
Chronic illness (mean ± sD) 1.08±0.84 0.98±0.85 1.10±0.83 0.183
Note: *Significantly different between groups by independent t-test, Fisher’s exact test, or χ2, as appropriate.
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in first second; FVC, forced vital capacity; SD, standard deviation.
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Discussion
The prevalence of undiagnosed AO among subjects with 
smoking history who participated in this study was 14.6%, 
which is similar to that reported in the study of Sekine et al 
conducted in Japan (13.1% prevalence among people with 
smoking history).17 The response rate of this cross-sectional 
survey (97.9%) was high. Most subjects were in the older 
age group with a relatively low educational level, who were 
likely to be representative of the public primary care clinics 
encounters in Hong Kong.32 On top of the overall prevalence 
of diagnosed COPD (3.5%) in Hong Kong,4 doctors were 
likely to diagnose more COPD patients with smoking his-
tory at the early stage of disease by the use questionnaire and 
spirometry test. If diagnosed at an early stage, COPD patients 
could potentially preserve their lung function by smoking 
cessation, thus preventing the subsequent development 
of complications and disabilities.8–10 This finding calls for 
a more active and effective screening of AO among patients 
with a smoking history. 
In contrast to the findings from recent studies showing 
the association of pack-years33 and age34 with risk of COPD, 
this study found no significant association of both factors 
with AO. The negative association with age could probably 
be explained by the relatively homogenous characteristics 
of the dominant older male population, which was a repre-
sentative of the smoker population in Hong Kong. Accord-
ing to the statistics in Hong Kong, the majority of cigarette 
smokers (82.8%) are male.22 Nevertheless, the number of 
years of smoking, calculated by subtracting the age at last 
smoking from the age at first smoking, showed significant 
association with AO (OR =1.044; P=0.035). This observa-
tion might be attributed to the fact that more than half of 
Table 2 Clinical characteristics of subjects with a history of smoking in primary care setting
Characteristics Total (n=731) Airflow obstruction: FEV1/FVC ,0.7
Yes (n=107) No (n=624) P-value*
Spirometric indices (mean ± SD)
Prebronchodilator
FEV1 (l) 2.6±0.8 2.2±0.7 2.7±0.8 ,0.001
FEV1 (% predicted) 106.3±24.6 93.3±25.5 108.5±23.8 ,0.001
FEV1/FVC (%) 78.2±9.1 62.8±6.3 80.9±6.4 ,0.001
FVC (L) 3.4±0.9 3.4±1.0 3.4±0.9 0.488
FVC (% predicted) 105.4±23.4 112.7±29.7 104.1±22.0 ,0.001
FeF 25%–75% 2.5±1.1 1.2±0.7 2.7±1.1 ,0.001
FeF 25%–75% (% predicted) 104.0±41.0 58.3±24.5 111.8±38.0 ,0.001
Postbronchodilator (n=58)
FEV1 (l) 2.1±0.6 2.1±0.6 2.0±0.6 0.888
FEV1 (% predicted) 89.9±23.0 90.2±22.8 88.9±24.4 0.867
FEV1/FVC (%) 68.0±10.3 65.2±9.4 77.6±6.9 ,0.001
FVC (L) 3.0±0.7 3.1±0.7 2.6±0.8 0.026
FVC (% predicted) 98.3±23.3 101.8±20.0 86.2±29.9 0.031
FeF 25%–75% 1.4±0.6 1.3±0.5 1.7±0.9 0.896
FeF 25%–75% (% predicted) 64.6±26.0 59.9±20.2 81.3±36.9 0.701
Pulmonary symptoms (mean ± SD; median, range)
Total BCss score 0.947±1.121; 1, 0–9 0.963±1.107; 1, 0–6 0.944±1.124; 0, 0–9 0.873
Breathlessness 0.071±0.297; 0, 0–2 0.065±0.284; 0, 0–2 0.072±0.299; 0, 0–2 0.829
Cough 0.378±0.571; 0, 0–3 0.364±0.521; 0, 0–2 0.380±0.579; 0, 0–3 0.798
sputum 0.498±0.598; 0, 0–4 0.533±0.619; 0, 0–2 0.492±0.594; 0, 0–4 0.515
Outcome measures
Asymptomatic AO (LFQ .18) 5 (4.8%), n=105
Symptomatic AO (LFQ #18) 100 (95.2%), n=105
GOLD classification of severity** (N=45) 
Mild COPD 27 (60.0%)
Moderate COPD 18 (40.0%)
severe COPD 0 (0.0%)
Very severe COPD 0 (0.0%)
Notes: *Significantly different between groups by independent t-test or χ2 test, as appropriate. **Assuming subjects with AO had COPD.
Abbreviations: AO, airflow obstruction; BCSS, Breathlessness, Cough, and Sputum Scale; COPD, chronic obstructive pulmonary disease; FEF, forced expiratory flow; FEV1, 
forced expiratory volume in the first second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; LFQ, Lung Function Questionnaire; 
sD, standard deviation.
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the subjects were past smokers (51.7%). There might have 
been recall bias or underreporting of the number of cigarettes 
smoked per day. In view of this, the conventional adoption 
of pack-years of smoking but not of duration of smoking to 
assess risk of AO should be reconsidered, especially when a 
significant proportion of screened subjects are ex-smokers. 
Both factors (ie, duration of smoking and pack-years) should 
be assessed in daily clinical practice. Further research is 
required in this area.
The majority of subjects had no or mild respiratory symp-
toms (eg, breathlessness, cough, or sputum) on the day of 
assessment as determined by the BCSS. However, it was found 
that the BCSS had no association with the diagnosis of AO. 
In other words, the presence of acute respiratory symptoms 
in patients with a history of smoking is not a helpful indicator 
of predicting AO. On the other hand, the presence of chronic 
symptoms by LFQ (eg, productive cough, wheezing, and 
shortness of breath) is a more accurate predictor of possible 
undiagnosed AO. Therefore, doctors should assess the dura-
tion of chronic respiratory symptoms in the patients with a 
history of smoking and order spirometry accordingly.
Apart from clinical symptoms and duration of smoking, 
another factor that is significantly associated with AO is 
whether a subject was of normal weight or underweight. 
It has been found that there is depletion of body weight, 
fat-free mass, and muscle mass in patients with moderate 
and severe COPD.31 In the present study, most subjects 
with AO suffered from mild lung function impairment, and 
the data would suggest that loss of body mass occurs early 
in the course of COPD. Further studies with more detailed 
nutritional assessment are required. 
Yet another observation was that subjects with hyperten-
sion had a significantly lower risk of AO. It is well known 
that hypertension and COPD commonly co-occur in the 
same individual, particularly in the elderly. Mills et al have 
in fact shown that patients with COPD have increased arte-
rial stiffness and blood pressure in comparison with controls 
matched for age and smoking status.35 Our findings seem 
to be contradictory to what is known about the relationship 
between COPD and systemic arterial hypertension. However, 
patients in the study by Mills et al had more severe conditions 
compared to those in the present study (Stage I, 2%; Stage 
II, 36%; Stage III, 39%; and Stage IV, 20%), which again 
raises the possibility that different stages of COPD may have 
different manifestations and associations. Further studies are 
thus required to examine the relationship between systemic 
arterial hypertension and different GOLD stages of COPD 
and thus to provide more definitive answers.
Table 3 Factors associated with undiagnosed airflow obstruction or undiagnosed chronic obstructive pulmonary disease by logistic 
regression
Characteristics Airflow obstruction: FEV1/FVC ,0.7 Airflow obstruction with chronic 
symptoms: LFQ scored #18 
OR 95% CI P-value OR 95% CI P-value
Sociodemographic
age (years) 1.037 (0.989–1.087) 0.134 1.038 (0.987–1.091) 0.147
Male 1.035 (0.356–3.015) 0.949 1.215 (0.372–3.971) 0.748
education (university or unknown) 0.803 0.751
Primary or below 1.203 (0.417–3.468) 0.733 1.506 (0.468–4.840) 0.492
Middle school 1.460 (0.489–4.355) 0.497 1.733 (0.519–5.787) 0.372
high school 1.088 (0.340–3.476) 0.887 1.261 (0.350–4.546) 0.723
Occupation (others) 0.729 0.809
retired 0.711 (0.301–1.678) 0.436 0.747 (0.300–1.858) 0.531
Working 0.840 (0.375–1.881) 0.671 0.865 (0.361–2.072) 0.745
Current smoker 1.191 (0.721–1.968) 0.495 1.288 (0.764–2.173) 0.342
Number of years of smoking 1.044 (1.003–1.087) 0.035 1.051 (1.007–1.096) 0.021
Pack-year 1.000 (0.991–1.010) 0.928 0.999 (0.989–1.010) 0.908
Clinical
Underweight or normal, BMI ,23 kg/m2 1.605 (1.009–2.552) 0.046 1.635 (1.012–2.639) 0.044
hypertension 0.491 (0.307–0.787) 0.003 0.520 (0.319–0.848) 0.009
Diabetes 0.655 (0.400–1.071) 0.092 0.679 (0.409–1.127) 0.134
Ischemic heart disease 1.625 (0.704–3.755) 0.256 1.716 (0.735–4.004) 0.212
stroke 0.490 (0.180–1.333) 0.162 0.508 (0.186–1.393) 0.188
Pulmonary symptoms in BCss score 0.954 (0.781–1.165) 0.642 0.981 (0.799–1.204) 0.853
Notes: Levels in parentheses are reference category of categorical variables. Values shown in bold indicate factors significantly associated with airflow obstruction.
Abbreviations: BCSS, Breathlessness, Cough, and Sputum Scale; BMI, body mass index; CI, confidence interval; FEV1, forced expiratory volume in the first second; FVC, 
forced vital capacity; LFQ, Lung Function Questionnaire; OR, odds ratio. 
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The response rate for spirometry test among the partici-
pants in the present study is very encouraging. It enhances 
the confidence of health care professionals that the test is 
well accepted by most of the primary care patients who are 
smokers. However, more than half (57.1%) of the subjects 
with AO who underwent preBD spirometry refused to undergo 
postBD spirometry. The research nurses in this project reported 
that most of the subjects who refused did not want to wait for 
the 15 minutes that was required to complete the test. Others 
simply did not want to blow again because of the physical 
discomfort associated with the test. However, although BD 
reversibility may provide useful clinical information, it is not 
required for the diagnosis of AO; therefore, the primary objec-
tive of this study was not adversely affected. LFQ in this study 
correlated well with the prevalence of AO, which was also 
demonstrated in a previous study.28 Possible future strategies 
to improve patient acceptance include a more widespread use 
of LFQ as a screening tool of AO, providing patients with clear 
explanation of procedures involved and educating them on the 
importance of completing both pre- and postBD spirometry. 
limitations
The majority of the study population (92.5%) were men from 
the older age group (mean age =62.2 years; SD =11.7) with 
a relatively low educational level and were unemployed. 
Therefore, the prevalence of AO could just be a representa-
tive of the male population of the lower socioeconomic class. 
The prevalence of AO among men of younger age group, 
women, and those from higher socioeconomic class may be 
different when using the same screening method. 
Although this method received a high response rate from 
the study population, the diagnosis of AO may not necessarily 
lead to the diagnosis of COPD. Other differential diagnoses 
such as asthma and bronchiectasis should also be considered 
in clinical practice. The relatively low response rate for 
postBD test may lead to underdetection of asthmatic element 
in subjects with AO. Even though screened subjects are clini-
cally compatible to COPD diagnosis, the severity cannot be 
graded due to the absence of postBD spirometry results. This 
limitation warrants a better designed screening program for 
AO with enhanced acceptance of postBD spirometry.
Conclusion
One in seven smokers who seek primary care services for 
various ailments in this study had undiagnosed AO. Although 
smokers who exhibited AO mostly suffered from COPD, 
all subjects in this study showed mild to moderate COPD 
condition. Most subjects with AO had chronic respiratory 
symptoms, although they might not show any acute respira-
tory symptoms. The presence of AO was associated with 
number of years of smoking, being normal or underweight, 
and having no hypertension. Spirometry screening of sub-
jects with smoking history, particularly those with chronic 
respiratory symptoms, should be considered to allow early 
diagnosis of AO, so that appropriate intervention measures 
including smoking cessation might be instituted.
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